Lexicon Pharmaceuticals (LXRX) Competitors

Lexicon Pharmaceuticals logo
$1.75 -0.04 (-2.23%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.75 0.00 (0.00%)
As of 11/16/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LXRX vs. XNCR, ZLAB, NAMS, RCUS, and CLDX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? Lexicon Pharmaceuticals's main competitors and comparable companies include Xencor (XNCR), Zai Lab (ZLAB), NewAmsterdam Pharma (NAMS), Arcus Biosciences (RCUS), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Xencor?

Xencor (NASDAQ:XNCR) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Xencor presently has a consensus target price of $42.22, indicating a potential upside of 19.27%. Lexicon Pharmaceuticals has a consensus target price of $5.80, indicating a potential upside of 231.43%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Xencor has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Xencor had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 9 mentions for Xencor and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.04 beat Xencor's score of 0.79 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lexicon Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xencor has a net margin of -58.79% compared to Lexicon Pharmaceuticals' net margin of -161.80%. Xencor's return on equity of -21.28% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
Lexicon Pharmaceuticals -161.80%-35.76%-24.53%

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M21.15-$91.92M-$1.59N/A
Lexicon Pharmaceuticals$49.80M15.65-$50.34M-$0.14N/A

Summary

Xencor beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zai Lab?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Zai Lab has a net margin of -44.91% compared to Lexicon Pharmaceuticals' net margin of -161.80%. Zai Lab's return on equity of -31.15% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals-161.80% -35.76% -24.53%
Zai Lab -44.91%-31.15%-18.17%

Lexicon Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$49.80M15.65-$50.34M-$0.14N/A
Zai Lab$460.16M6.38-$175.54M-$1.79N/A

In the previous week, Zai Lab had 7 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 14 mentions for Zai Lab and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.04 beat Zai Lab's score of 0.64 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lexicon Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Lexicon Pharmaceuticals currently has a consensus target price of $5.80, indicating a potential upside of 231.43%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 58.71%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Summary

Lexicon Pharmaceuticals and Zai Lab tied by winning 8 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.04 beat NewAmsterdam Pharma's score of 0.28 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lexicon Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NewAmsterdam Pharma has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lexicon Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M103.73-$203.82M-$1.69N/A
Lexicon Pharmaceuticals$49.80M15.65-$50.34M-$0.14N/A

Lexicon Pharmaceuticals has a net margin of -161.80% compared to NewAmsterdam Pharma's net margin of -789.95%. NewAmsterdam Pharma's return on equity of -31.39% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Lexicon Pharmaceuticals -161.80%-35.76%-24.53%

NewAmsterdam Pharma currently has a consensus price target of $49.82, suggesting a potential upside of 156.00%. Lexicon Pharmaceuticals has a consensus price target of $5.80, suggesting a potential upside of 231.43%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Lexicon Pharmaceuticals beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Arcus Biosciences has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Arcus Biosciences presently has a consensus target price of $39.36, indicating a potential upside of 133.63%. Lexicon Pharmaceuticals has a consensus target price of $5.80, indicating a potential upside of 231.43%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$247M9.82-$353M-$3.63N/A
Lexicon Pharmaceuticals$49.80M15.65-$50.34M-$0.14N/A

In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 3 mentions for Arcus Biosciences. Lexicon Pharmaceuticals' average media sentiment score of 1.04 beat Arcus Biosciences' score of 0.26 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Lexicon Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -161.80% compared to Arcus Biosciences' net margin of -453.00%. Lexicon Pharmaceuticals' return on equity of -35.76% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-453.00% -91.65% -46.72%
Lexicon Pharmaceuticals -161.80%-35.76%-24.53%

Summary

Lexicon Pharmaceuticals beats Arcus Biosciences on 11 of the 15 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Celldex Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Celldex Therapeutics and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.04 beat Celldex Therapeutics' score of 0.92 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lexicon Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lexicon Pharmaceuticals currently has a consensus target price of $5.80, indicating a potential upside of 231.43%. Celldex Therapeutics has a consensus target price of $64.08, indicating a potential upside of 124.48%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Lexicon Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$49.80M15.65-$50.34M-$0.14N/A
Celldex Therapeutics$1.54M1,456.32-$258.76M-$4.30N/A

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -161.80%. Lexicon Pharmaceuticals' return on equity of -35.76% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals-161.80% -35.76% -24.53%
Celldex Therapeutics N/A -52.66%-47.58%

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LXRX vs. The Competition

MetricLexicon PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$810.33M$4.15B$7.83B$12.17B
Dividend YieldN/A3.62%2.46%4.42%
P/E RatioN/A26.5433.3827.85
Price / Sales15.6516.048.595.73
Price / CashN/A26.3721.9322.50
Price / Book4.734.074.403.70
Net Income-$50.34M-$22.86M$3.52B$392.17M
7 Day Performance-5.91%-6.15%-4.48%-3.37%
1 Month Performance15.13%-4.92%-3.53%-5.82%
1 Year Performance19.86%-3.09%0.12%-6.24%

Lexicon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LXRX
Lexicon Pharmaceuticals
2.7621 of 5 stars
$1.75
-2.2%
$5.80
+231.4%
+17.4%$810.33M$49.80MN/A81
XNCR
Xencor
2.4097 of 5 stars
$38.59
+7.9%
$42.22
+9.4%
+137.1%$2.60B$125.58MN/A260
ZLAB
Zai Lab
3.4683 of 5 stars
$26.86
+5.4%
$37.25
+38.7%
+7.9%$2.59B$460.16MN/A1,784
NAMS
NewAmsterdam Pharma
3.3957 of 5 stars
$19.00
+0.5%
$48.70
+156.3%
-49.3%$2.50B$22.50MN/A100
RCUS
Arcus Biosciences
2.9192 of 5 stars
$18.90
+3.4%
$39.36
+108.3%
-16.1%$2.46B$247MN/A601

Related Companies and Tools


This page (NASDAQ:LXRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners